addex therapeutics is pioneering discovery and development of an emerging class of oral small molecule drugs, called allosteric modulators, which can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. the company uses its proprietary discovery platform to address receptors and other proteins that have been undruggable for conventional drug discovery methods, including g-protein coupled receptors (gpcrs), receptor tyrosine kinases (rtks) and cytokine receptors, such as the tnf receptor superfamily. many such targets have been widely recognized as attractive for modulation of important diseases with unmet medical needs, but have remained inaccessible to small molecule drug discovery. the company’s two lead products are: dipraglurant (adx48621), an mglur5 negative allosteric modulator, or nam, which reduced parkinson’s disease levodopa-induced dyskinesia (pd-lid) in a phase ii
Company profile
Ticker
ADXN
Exchange
Website
CEO
Tim Dyer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ADXN stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
23 Apr 24
POS AM
Prospectus update (post-effective amendment)
18 Apr 24
20-F
2023 FY
Annual report (foreign)
18 Apr 24
6-K
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
18 Apr 24
6-K
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
3 Apr 24
424B5
Prospectus supplement for primary offering
30 Jan 24
6-K
Current report (foreign)
30 Jan 24
6-K/A
Current report (foreign) (amended)
21 Dec 23
6-K
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
20 Dec 23
6-K
Addex Creates Treasury Shares
14 Dec 23
Latest ownership filings
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
8 Dec 23
SC 13D/A
Dyer Timothy Mark
29 Nov 23
SC 13D/A
Growth Equity Opportunities Fund IV, LLC
10 Apr 23
SC 13D/A
Dyer Timothy Mark
5 Apr 23
SC 13D/A
Dyer Timothy Mark
31 Mar 23
SC 13G/A
ARMISTICE CAPITAL, LLC
16 Feb 23
SC 13G/A
CAXTON CORP
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
New Leaf Biopharma Opportunities I, L.P.
6 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 625.33 mm |
Total shares | 10.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Growth Equity Opportunities Fund IV | 7.70 mm | $0.00 |
New Leaf Biopharma Opportunities I | 2.32 mm | $0.00 |
Armistice Capital | 537.00 k | $206.37 mm |
NEA Management | 180.00 k | $408.29 mm |
Baader Bank | 19.20 k | $6.58 mm |
Jane Street | 10.58 k | $4.07 mm |
UBS UBS Group AG - Registered Shares | 74.00 | $28.00 k |
Proequities | 0.00 | $0.00 |
News
Earnings Scheduled For April 18, 2024
18 Apr 24
Addex Therapeutics FY23 EPS CHF (0.14) Up From CHF (0.46) YoY, Income CHF 1.65M Up From CHF 1.45M YoY
18 Apr 24
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Apr 24
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
16 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Apr 24
Press releases
Addex to Present at the Swiss Biotech Day 2024
19 Apr 24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
18 Apr 24
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
11 Apr 24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
3 Apr 24